Investing.com - Evaxion Biotech AS (NASDAQ: EVAX) reported second quarter EPS of $-0.210, $0.03 better than the analyst estimate of $-0.243. Revenue for the quarter came in at...
Investing.com - Evaxion Biotech AS (NASDAQ: EVAX) reported first quarter EPS of $-0.240, $0.06 better than the analyst estimate of $-0.300. Revenue for the quarter came in at $0.00...
Investing.com - Evaxion Biotech AS (NASDAQ: EVAX) reported first quarter EPS of $-0.290, $0.03 worse than the analyst estimate of $-0.263. Revenue for the quarter came in at $0.00...
Investing.com - Evaxion Biotech AS reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations. Evaxion Biotech AS...
Evaxion Biotech A/S (EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that...
Evaxion Biotech A/S (EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a...
Evaxion Biotech A/S (EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a...
Evaxion Biotech A/S (EVAX) today announced:Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business...